title: Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms.
abstract: Urokinase plasminogen activator (uPA) has been implicated in the healing responses of injured arteries, but the importance of its various properties that influence smooth muscle cell (SMC) proliferation and migration in vivo is unclear. We used three recombinant (r-) forms of uPA, which differ markedly in their proteolytic activities and abilities to bind to the uPA receptor (uPAR), to determine, which property most influences the healing responses of balloon catheter injured rat carotid arteries. After injury, uPA and uPAR expression increased markedly throughout the period when medial SMCs were rapidly proliferating and migrating to form the neointima. Perivascular application of uPA neutralizing antibodies immediately after injury attenuated the healing response, significantly reducing neointima size and neointimal SMC numbers. Perivascular application of r-uPAwt (wild type uPA) or r-uPA/GDF (r-uPA with multiple mutations in its growth factor-like domain) doubled the size of the neointima. Four days after injury these two uPAs nearly doubled neointimal and medial SMC numbers in the vessels, and induced greater reductions in lumen size than injury alone. Proteolytically inactive r-uPA/H/Q (containing glutamine rather than histidine-204 in its catalytic site) did not affect neointima or lumen size. Also, in contrast to the actions of proteolytically active uPAs, tissue plasminogen activator (tPA) did not affect the rate of neointima development. We conclude that uPA is an important factor regulating the healing responses of balloon catheter injured arteries, and its proteolytic property, which cannot be mimicked by tPA, greatly influences SMC proliferation and early neointima formation.
authors.affiliation: Molecular Endocrinology Laboratory, Institute of Experimental Cardiology, Cardiology Research Center, 121552, Moscow, Russia.
authors.forename: O
authors.initials: O
authors.lastname: Plekhanova
authors.forename: Y
authors.initials: Y
authors.lastname: Parfyonova
authors.forename: R
authors.initials: R
authors.lastname: Bibilashvily
authors.forename: S
authors.initials: S
authors.lastname: Domogatskii
authors.forename: V
authors.initials: V
authors.lastname: Stepanova
authors.forename: D C
authors.initials: DC
authors.lastname: Gulba
authors.forename: A
authors.initials: A
authors.lastname: Agrotis
authors.forename: A
authors.initials: A
authors.lastname: Bobik
authors.forename: V
authors.initials: V
authors.lastname: Tkachuk
mesh_terms: D000704:Analysis of Variance; D000800:Angioplasty, Balloon; D000818:Animals; D001483:Base Sequence; D020212:Carotid Artery Injuries / Q000201:enzymology* / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects* / Q000502:physiology; D002478:Cells, Cultured; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D008297:Male; D008969:Molecular Sequence Data; D010447:Peptide Hydrolases / Q000378:metabolism; D011336:Probability; D051381:Rats; D011921:Rats, Inbred WKY; D012016:Reference Values; D012038:Regeneration / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017539:Tunica Intima / Q000166:cytology / Q000201:enzymology / Q000378:metabolism*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D010447:Peptide Hydrolases; D014568:Urokinase-Type Plasminogen Activator